The susceptibility of 105 thermophilic campylobacters from human and swine origins to eight macrolides and related compounds was tested. Erythromycin, josamycin, clindamycin, and ASE 136 BS (a new erythromycin derivative) were the most active against the human strains. The swine strains were highly resistant, except to pristinamycin. The human Campylobacter coli strains (except for two strains) behaved like the C. jejuni strains.
study was to determine the susceptibility of C. jejini and C. coli to macrolides and the related compounds lincomycin, clindamycin, and pristinamycin as well as to a new compound, ASE 136 BS.
Seventy-nine strains of human origin were tested: 55 C. jejuni and 24 C. coli isolated in France (32 strains), Vietnam (11 strains), the United States (6 strains), Australia (8 strains), and Hungary (22 strains). Twenty-six C. coli strains from swine origin isolated in France (20 strains) and the United States (6 strains) were also tested. All these strains were isolated from fecal samples on a selective medium except for those from Australia, which were isolated by a filtration technique.
The strains were identified by the following characteristics: morphology, oxidase and catalase tests, and growth at 42°C in a microaerophilic atmosphere. The hippurate test was used to differentiate C. jejuni (hippurate positive) and C. coli (hippurate negative) (10 p.g/ml) reacting like the swine C. coli strains. All the C. coli strains resistant at a high level were also resistant to josamycin, clindamycin, and ASE 136 BS, except for two: one was susceptible to clindamycin and ASE 136 BS, and the other was susceptible only to clindamycin.
Pristinamycin seemed to have the same activity against all the strains, in contrast to the other compounds tested.
We did not notice any special behavior for the human strains from different countries. The two highly resistant C. coli strains of human origin were from France.
Data concerning the susceptibility of campylobacters to the macrolides or related compounds are scarce. All of the campylobacter-antibiotic studies included erythromycin, which is the most widely prescribed antibiotic for the treatment of campylobacter enteritis, and sometimes clindamycin, but not the others. This results of our study are in agreement with the fact that these two agents are among the most effective. Josamycin was found to be slightly superior to (15), 12% (13, 18) , and 17% (19; Pritivera et al., 13th Int. Congr. Chemother.). These differences may be related to the method used or to the threshold used to classify a strain as resistant (4 or 8 p.g/ml); however, there is also the possibility that the differences may be related to the number of C. coli strains included. In less recent studies, differentiation of the strains on the basis of hippurate hydrolysis was not carried out. All the strains were called C. fetus subsp. jejuni or C. jejuni. We now know that the percentage of C. coli strains isolated may vary widely from one area to another and, therefore, because of their different antibiotic resistance patterns, they can influence the results. In only four studies performed in 1984 (4, 7, 16, 24) was C. coli also included, and in only two studies (18, 24) was the origin of the strains, e.g., swine, well documented.
Our results are in agreement with those of Secker (16), Burridge and Phillips (4), and Wang et al. (24) , who found C. coli to be significantly more resistant to erythromycin than C. jejuni, but the human C. coli were not as resistant as the swine C. coli, as we have previously shown (6) . We hypothesize that the more highly resistant strains isolated from swine could be the result of exposure of these strains to a macrolide addition in the diet of these animals. This hypothesis is currently under study.
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